INDICATION
arrow

MOVANTIK® (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.

FAQs

Help start the OIC conversation—
know what your patients might be asking

Opioid-induced constipation
What is opioid-induced constipation?

Opioids are prescription medicines like codeine, hydrocodone, morphine, oxycodone, fentanyl, and tramadol that are used to treat pain. Opioid-induced constipation is one of the most common side effects of opioid use.1-3

Opioids block pain signals by attaching to something called mu-receptors in the brain and other parts of the central nervous system. However, opioids also attach to mu-receptors in the bowel, which can cause opioid-induced constipation.4

MOVANTIK
What is MOVANTIK and who is it for?

MOVANTIK is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.5

MOVANTIK—one pill once a day—is specifically designed for OIC in adults with chronic non-cancer pain. It works by blocking opioids from binding to something called mu-receptors in your bowel.5

How long does it take for MOVANTIK to work?

In clinical studies, MOVANTIK worked quickly, often within 6 to 12 hours of the first dose.5

How is MOVANTIK different from many other treatments for constipation?

MOVANTIK is a prescription medicine specifically for constipation from opioids in adults with chronic non-cancer pain.5

Will taking MOVANTIK change the way patients take their opioid pain medication?

When starting MOVANTIK, changes to a patient's opioid dosing regimen are not required.5

What are the possible side effects of MOVANTIK?

MOVANTIK may cause serious side effects, including5:

Opioid withdrawal.

  • Patients may have symptoms of opioid withdrawal during treatment with MOVANTIK including sweating, chills, diarrhea, stomach pain, anxiety, irritability, and yawning. If patients take methadone, they may be more likely to have stomach pain and diarrhea than people who do not take methadone

Severe stomach pain or diarrhea, or both severe stomach pain and diarrhea.

  • Severe stomach pain and diarrhea can happen when taking MOVANTIK. These problems can happen within a few days after starting MOVANTIK and can lead to hospitalization. Patients should stop taking MOVANTIK and call a healthcare provider right away if they have severe stomach pain or diarrhea, or both severe stomach pain and diarrhea

Tear in your stomach or intestinal wall (perforation).

  • Stomach pain that is severe can be a sign of a serious medical condition. If patients have stomach pain that gets worse or does not go away, stop taking MOVANTIK and get emergency medical help right away

The most common side effects of MOVANTIK include: stomach (abdomen) pain, diarrhea, nausea, flatulence, vomiting, and headache.5

Patients should tell their healthcare provider if they have any side effect that bothers them or that does not go away. These are not all the possible side effects of MOVANTIK.

Click here for the Important Safety Information, Medication Guide, and US Full Prescribing Information for MOVANTIK.

How should patients take MOVANTIK?

Patients should take MOVANTIK exactly as their health care provider prescribes. MOVANTIK should be taken 1 time each day, on an empty stomach, at least 1 hour before the first meal of the day or 2 hours after the meal. Patients should also stop taking other laxatives before they start treatment with MOVANTIK. A health care provider may prescribe other laxatives if MOVANTIK does not work after 3 days of treatment.5

Where can I find the MOVANTIK Prescribing Information?

Click here to see the MOVANTIK Prescribing Information.

Savings and coverage
Is MOVANTIK covered by insurance?

The majority of commercial patients* nationwide are covered for MOVANTIK. Patients can ask their pharmacist or insurance provider.6

*“Patients” means covered lives (Commercial, Commercial [BCBS], Employer, Federal Employees Health Benefit Plans [FEHBPs], Federal Programs, Municipal Plan, Pharmacy Benefit Manager [PBM], Union) at Tiers 1-7 and the $0 Co-pay tier in the region, as calculated by Managed Markets Insight & Technology, LLC database as of June 24, 2020.
“Covered” means any coverage level, specifically Tiers 1-7 and the $0 Co-pay tier, regardless of restrictions.
How much does MOVANTIK cost?

With the MOVANTIK savings card, eligible patients pay as little as $0 per month for MOVANTIK.* That’s less than the cost of over-the-counter laxatives.†7

*Subject to complete eligibility rules; restrictions apply. See eligibility information and instructions. If eligible, show your card and prescription to your pharmacist for instant savings.
Over-the-counter laxatives include Colace®, Dulcolax®, ex-lax®, MiraLAX®, Peri-Colace®, Senokot®, and Senokot-S®. Pricing comparisons do not imply comparable efficacy, safety, or FDA-approved indications.

ELIGIBILITY:
You may be eligible for this offer if you are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions.

Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.

If you are enrolled in a state or federally funded prescription insurance program, you may not use this Savings Card even if you elect to be processed as an uninsured (cash-paying) patient.

This offer is not insurance and is restricted to residents of the United States and Puerto Rico and patients over 18 years of age. This offer is valid for retail prescriptions only.

TERMS OF USE:
Eligible commercially insured patients with a valid prescription for MOVANTIK® (naloxegol) tablets who present this Savings Card at participating pharmacies will pay $0 per 30-day supply, subject to a maximum savings of $100 per 30-day supply. Cash-paying patients will receive up to $100 in savings on out-of-pocket costs that exceed $0 per 30-day supply. This offer is good for 12 uses and each 30-day supply counts as 1 use. Other restrictions may apply. Patient is responsible for applicable taxes, if any. If you have any questions regarding this offer, please call 1-984-444-7010.

Offer expires on 12/31/2021.

Non-transferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed, or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. RedHill Biopharma reserves the right to rescind, revoke, or amend this offer, eligibility, and terms of use at any time without notice. This offer is not conditioned on any past, present, or future purchase, including refills. Offer must be presented along with a valid prescription for MOVANTIK® (naloxegol) tablets at the time of purchase.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Program managed by ConnectiveRx on behalf of RedHill Biopharma Inc.

OIC=opioid-induced constipation.
References: 1. Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269-281. 2. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181-1187. 3. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009;373:1198-1206. 4. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847-1865. 5. MOVANTIK® (naloxegol). Prescribing information. RedHill Biopharma Inc; 2020. 6. Data on file. Managed Markets Insight & Technology coverage data. RedHill Biopharma Inc; 2020. 7. CVS Pharmacy. Accessed November 3, 2020. https://www.cvs.com/shop
IMPORTANT SAFETY INFORMATION ABOUT MOVANTIK
  • MOVANTIK® (naloxegol) is contraindicated in:
    • Patients with known or suspected gastrointestinal (GI) obstruction and patients at risk of recurrent obstruction, due to the potential for GI perforation
    • Patients receiving strong CYP3A4 inhibitors (eg, clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms
    • Patients with a known serious or severe hypersensitivity reaction to MOVANTIK or any of its excipients
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with MOVANTIK. Patients receiving methadone as therapy for their pain condition were observed in the clinical trials to have a higher frequency of GI adverse reactions that may have been related to opioid withdrawal than patients receiving other opioids. Patients with disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal or reduced analgesia. These patients (eg, multiple sclerosis, recent brain injury, Alzheimer's disease, and uncontrolled epilepsy) were not enrolled in the clinical studies. Take into account the overall risk-benefit profile when using MOVANTIK in such patients. Monitor for symptoms of opioid withdrawal when using MOVANTIK in such patients
  • Severe abdominal pain and/or diarrhea have been reported, generally within a few days of initiation of MOVANTIK. Monitor and discontinue if severe symptoms occur. Consider restarting MOVANTIK at 12.5 mg once daily
  • Cases of GI perforation have been reported with the use of peripherally acting opioid antagonists, including MOVANTIK. Postmarketing cases of GI perforation, including fatal cases, were reported when MOVANTIK was used in patients at risk of GI perforation (eg, infiltrative gastrointestinal tract malignancy, recent gastrointestinal tract surgery, diverticular disease including diverticulitis, ischemic colitis, or concomitantly treated with bevacizumab). Monitor for severe, persistent, or worsening abdominal pain; discontinue if this symptom develops
  • Avoid concomitant use of moderate CYP3A4 inhibitors (eg, diltiazem, erythromycin, verapamil) because they may increase the risk of adverse reactions. Use of strong CYP3A4 inducers (eg, rifampin, carbamazepine, St. John’s Wort) is not recommended because they may decrease the efficacy of MOVANTIK. Avoid concomitant use of MOVANTIK with another opioid antagonist due to the increased risk of opioid withdrawal
  • The use of MOVANTIK during pregnancy may precipitate opioid withdrawal in the pregnant woman and the fetus. Because of the potential for adverse reactions, including opioid withdrawal in breastfed infants, advise women that breastfeeding is not recommended during treatment with MOVANTIK
  • The most common adverse reactions with MOVANTIK as compared to placebo in clinical trials were: abdominal pain (21% vs 7%), diarrhea (9% vs 5%), nausea (8% vs 5%), flatulence (6% vs 3%), vomiting (5% vs 4%), headache (4% vs 3%), and hyperhidrosis (3% vs <1%)
INDICATION

MOVANTIK® (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.

You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

RedHill Biopharma Inc. supports the responsible use of medications, including those containing opioids, as treatment options for patients with chronic non-cancer pain.

This site is intended for US health care professionals only.

RedHill Biopharma Inc. (U.S. Office)
8045 Arco Corporate Drive, Suite 200
Raleigh, NC 27617
Tel: +1-984-444-7010
Fax: +1-919-406-0400
info@redhillus.com

The information on the following site is intended for US health care professionals. Please choose:

I am not a US health care professional

GO BACK

I am a US health care professional

CONTINUE

Think you have opioid-induced constipation?

Think you have opioid-induced constipation?

Begin the quiz

Are you currently taking any opioid pain medication(s) for chronic non-cancer pain?

Select one

Yes
No
Not sure
Submit

MOVANTIK is meant for people taking opioids in order to treat opioid-induced constipation in adults with chronic non-cancer pain.

If you’re experiencing constipation, talk to your doctor about your options for treatment.2,3

Go back

How many bowel movements do you have per week?

Select one

≤1
2-3
4 or more
Submit

MOVANTIK is for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. Having less than 3 bowel movements per week while taking opioids can be a symptom of opioid-induced constipation.

If you’re experiencing constipation, talk to your doctor
about your options for treatment.2,3

Go back

When completing a bowel movement, have you experienced any of the following?

Select all that apply

Straining
Hard or lumpy
stools
Sense of incomplete evacuation
Submit

You may have opioid-induced constipation.1-3

Talk to you doctor about your symptoms and learn how
MOVANTIK may be able to help.

References: 1. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847-1865. 2. MOVANTIK® (naloxegol). Prescribing information. RedHill Biopharma Inc; 2020. 3. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387-2396.